Fig. 1: Overall survival of the entire population of 142 CLL patients according to SRSI. | Blood Cancer Journal

Fig. 1: Overall survival of the entire population of 142 CLL patients according to SRSI.

From: Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab

Fig. 1

(β2 M ≤ 5 = 0 points; β2 M > 5 = 1 point; hemoglobin > 11 g/L for women and > 12 g/L for men = 0 points; hemoglobin ≤ 11 g/L for women and ≤ 12 g/L for men = 2 points; LDH ≤ UNL = 0 points; LDH > UNL = 2 points; total score 0 = low risk; score 1–3 = intermediate risk; score 4–5 = high risk).

Back to article page